StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.57−0.13 (-3.51%)

Close on Nov 18, 2026Market cap $99.44MP/E –Yield –

Unicycive Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Unicycive Therapeutics's total assets was $72.03M at Jun 30, 2026. For fiscal 2025 it was $49.14M, up 55.2% from the year before. The highest annual figure on record is $49.14M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$49.14M+55.2%
FY2024Dec 31, 2024$31.67M+123.2%
FY2023Dec 31, 2023$14.19M+403.6%
FY2022Dec 31, 2022$2.82M-85.0%
FY2021Dec 31, 2021$18.74M+9088.2%
FY2020Dec 31, 2020$204.00K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$72.03M+140.1%
Q1 FY2026Mar 31, 2026$64.41M+130.5%
Q4 FY2025Dec 31, 2025$49.14M+55.2%
Q3 FY2025Sep 30, 2025$50.61M+31.2%
Q2 FY2025Jun 30, 2025$30.00M-32.9%
Q1 FY2025Mar 31, 2025$27.95M-46.7%
Q4 FY2024Dec 31, 2024$31.67M+123.2%
Q3 FY2024Sep 30, 2024$38.57M+98.4%
Q2 FY2024Jun 30, 2024$44.70M+95.3%
Q1 FY2024Mar 31, 2024$52.39M+92.6%
Q4 FY2023Dec 31, 2023$14.19M+403.6%
Q3 FY2023Sep 30, 2023$19.44M+91.0%
Q2 FY2023Jun 30, 2023$22.88M+78.6%
Q1 FY2023Mar 31, 2023$27.20M+72.6%
Q4 FY2022Dec 31, 2022$2.82M-85.0%
Q3 FY2022Sep 30, 2022$10.18M-48.6%
Q2 FY2022Jun 30, 2022$12.82M+1303.7%
Q1 FY2022Mar 31, 2022$15.76M+7625.5%
Q4 FY2021Dec 31, 2021$18.74M–
Q3 FY2021Sep 30, 2021$19.78M–
Q2 FY2021Jun 30, 2021$913.00K–
Q4 FY2020Dec 31, 2020$204.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?